Our approach combines precision immunology and T-cell engineering to create therapies that detect and eliminate ALK-driven tumors with unmatched specificity—offering new hope where resistance has taken hold.
Shaping a future where ALK+ cancers no longer dictate the outcome.
ALKemist Bio has appointed Dr. Adi Hoess as an independent Board member. With over 30 years of leadership in immuno-oncology and cell therapies, Dr. Hoess brings valuable expertise as the company advances its ALK-specific T cell therapies toward clinical development. His experience, including a 13-year tenure as CEO of Affimed, will support ALKemist’s mission to improve outcomes for patients with aggressive ALK-positive cancers.
ALKemist Bio signs exclusive license with Boston Children’s Hospital and launches a 2-year research deal to develop TCR therapies for ALK-positive tumors, advancing novel cancer treatments from Prof. Chiarle’s groundbreaking research.
ALKemist Bio, biotech startup from Turin, raises €6.9M to develop first-in-class TCR cell therapies targeting ALK-positive tumors, based on research by Prof. Roberto Chiarle, aiming to offer innovative treatments for aggressive cancers.
